1. All-trans retinoic acid (ATRA) has been found to target gastric cancer stem cells and inhibit the growth of patient-derived gastric carcinoma tumors.
2. ATRA was found to reduce the number of cancer stem cells in vitro, as well as reduce tumor size in vivo.
3. The authors suggest that ATRA may be a potential therapeutic option for treating gastric cancer.
The article is generally reliable and trustworthy, as it is based on research conducted by a team of experienced scientists and published in a reputable journal. The authors provide evidence for their claims, such as data from experiments conducted both in vitro and in vivo, which supports their conclusions. Furthermore, the authors discuss potential limitations of their study, such as the small sample size used for the experiments, which adds to its credibility.
However, there are some points that could be improved upon. For example, the authors do not explore any possible risks associated with using ATRA as a treatment option for gastric cancer or discuss any potential side effects that may arise from its use. Additionally, they do not present any counterarguments or alternative treatments that could be used instead of ATRA. Finally, there is no discussion of how this research could be applied in clinical settings or what further research needs to be done before it can be implemented into practice.